来氟米特片联合肾易通颗粒治疗系膜增生性肾小球肾炎临床疗效分析

目的分析来氟米特片联合肾易通颗粒治疗系膜增生性肾小球肾炎的临床效果。方法采用病例对照分析研究,将65例患者随机分为来氟米特组(25例)、来氟米特加肾易通组(20例)、肾易通组(20例)。观察临床症状、体征以及尿常规、尿红细胞计数、24 h尿蛋白定量、血清白蛋白(ALB)、血常规、血尿素氮、血肌酐(Ser)、谷丙转氨酶、谷草转氨酶的变化以及用药期间不良反应。结果来氟米特组各疗程有效率虽较肾易通组高,但差异无显著性(P>0.05);来氟米特加肾易通组治疗6个月后的疗效(100%)不仅优于肾易通组(P<0.05),而且优于来氟米特组(P<0.05)。结论来氟米特联合肾易通颗粒对系膜增生性肾小球肾炎患者具有疗效好、不良反应少的特点,值得临床推广。

Clinical efficacy analysis on leflunomide and Shenyitong Granule combination in treatment of mesangial proliferative glomerulonephritis

Objective To observe the clinical efficacy of leflunomide and Shenyitong Granule combination in treatment of mesangial proliferative glomerulonephritis.Methods Sixty-five patients were randomly divided into the leflunomide group(25 cases),leflunomide plus Shenyitong Granule group(20 cases),and Shenyitong Granule group(20 cases).Clinical symptoms,signs,urine,24 h urinary protein excretion,serum albumin(ALB),urinary red blood cell count,blood count,blood urea nitrogen,serum creatinine(Ser),alanine aminotransferase,and aspartate aminotransferase were tested as well as the adverse reactions were observed during the treatment.Results There were no significant difference between leflunomide group and Shenyitong Granule group(P>0.05).Six months later,the efficacy of leflunomide plus Shenyitong Granule group(100%) was better than Shenyitong Granule group(P<0.05) and the leflunomide group(P<0.05).Conclusion In combination of leflunomide and Shenyitong Granule are effective in treatment of mesangial proliferative glomerulonephriti with little adverse reaction and fewer side effects,which is worth of spreading in clinic.